 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Bone Complications
|
|
Denosumab Delays Skeletal-related Events in Cancer Patients with Bone Metastases (9/22/2009)
Researchers involved in a multicenter Phase III study have reported that denosumab is at least as effective as Zometa® (zoledronic acid) in delaying skeletal-related events (SREs) in cancer patients with bone metastases. The details of this study were presented at the ECCO 14- ESMO 34 Congress in Berlin on September 20 as a late-breaking abstract.
Denosumab Shows Bone Benefits in Two Pivotal Studies (8/11/2009)
Denosumab increases bone mineral density (BMD) and reduces the risk of vertebral fractures in women with postmenopausal osteoporosis as well as men treated with androgen deprivation therapy for non-metastatic prostate cancer, according to the results of two pivotal studies published in the New England Journal of Medicine.
Denosumab Effective in Patients with Bone Metastases (8/10/2009)
Among patients with bone metastases from cancers other than breast cancer or prostate cancer, the investigational drug denosumab was as effective as Zometa® (zoledronic acid) at reducing the risk of bone complications such as fracture. The results of this Phase III clinical trial were made available in a press release from Amgen.
Denosumab More Effective than Zometa® in Patients with Bone Metastases (7/10/2009)
A press release from Amgen has reported that denosumab was more effective than Zometa® (zoledronic acid) for the prevention of bone complications in women with metastatic bone disease from breast cancer. These results were obtained in a large Phase III clinical trial comparing denosumab to Zometa for prevention of bone complications.
Denosumab Benefits Patients with Bone Metastases Who Have Received Bisphosphonates (4/6/2009)
Researchers from France have reported that patients with bone metastases who are treated with denosumab have a greater reduction in urinary N-telopeptide and fewer skeletal-related events than patients continuing to receive bisphosphonates. The details of this study appeared in the April 1, 2009 issue of the Journal of Clinical Oncology.
Risk of Bisphosphonate Induced Osteonecrosis of the Jaw Defined (7/6/2007)
Researchers from the University of Texas at Galveston have reported that osteonecrosis of the jaw increases 9 fold with more than 21 infusions of bisphosphonates. The details of this study appeared in the July 4, 2007 issue of the Journal of the National Cancer Institute.
Reduced Schedule of Zometa® May Decrease the Incidence of Osteonecrosis of the Jaw (6/29/2007)
Researchers from Italy have reported that monthly treatment with Zometa (zoledronic acid) followed by treatment every 3 months can reduce the incidence of osteonecrosis of the jaw compared to continued monthly dosing in patients with multiple myeloma. The details of this study appeared in the July, 2007 issue of Leukemia.
Progressive Increase in Osteoporosis with Long-Term Androgen Deprivation (4/20/2007)
Researchers from Barcelona, Spain, have reported that the prevalence of osteoporosis is high before treatment and progressively increases with long-term androgen deprivation therapy (ADT). The details of this study appeared in the March 2007 issue of Urology.
Aromasin® Compromises Bone Health in Breast Cancer Patients (1/31/2007)
Researchers associated with the Intergroup Extemestane Study (IES) have reported that women with breast cancer who switch from Nolvadex® (tamoxifen) to Aromasin (exemestane) have an increased risk of bone fractures. However, it was also noted that overall survival is improved with Aromasin.
Zometa® Prevents Bone Loss in Premenopausal Breast Cancer Patients (1/17/2007)
Researchers affiliated with the Austrian Breast and Colorectal Cancer Study Group have reported that Zometa (zoledronic acid) prevented bone loss in premenopausal patients receiving adjuvant endocrine therapy for hormone-responsive breast cancer.
Patients with Breast Cancer Bone Metastasis Failing Bonefos® or Aredia® Benefit From Zometa® (10/31/2006)
Researchers from Canada have reported Zometa® (zoledronic acid) can improve pain control in patients with breast cancer who have worsening of bone metastases during bisphosphonate therapy with Aredia® (pamidronate) or Bonefos® (clodronate).
Prevention and Management of Bisphosphonate Toxicities Reviewed (8/15/2006)
Researchers from the H. Lee Moffitt Cancer Center and Loyola University have published suggestions for the management of adverse effects associated with intravenous bisphosphonate therapy.
Zometa® May Prevent Bone Loss Associated With Androgen Suppression for Prostate Cancer (8/9/2006)
Researchers from Oregon Health and Science University, the University of Chicago and Pennsylvania State University College of Medicine have reported that Zometa (zoledronic acid) may prevent bone loss associated with androgen deprivation treatment (ADT) for prostate cancer without metastases when started during the first year of therapy.
Zometa® Reduces Cancer Progression Over Clondronate® (6/6/2006)
The bisphosphonate Zometa (zoledronic acid) significantly reduces the progression of disease in subgroups of patients compared to Clodronate (pamidronate) in women with breast cancer that has metastasized to the bone. Results from this retrospective analysis including data from a phase III clinical trial comparing Zometa to Clodronate were presented at the 42nd annual meeting of the American Society of Clinical Oncology.
Anti-Androgen Therapy for Prostate Cancer Increases Risk of Fractures (1/19/2006)
Researchers from Massachusetts General Hospital have reported that the use of gonadotropin-releasing hormone (GnRH) agonist therapy increases the risk of fractures in men with prostate cancer.
Patients with Breast Cancer Bone Metastasis Failing Clodronate or Pamidronate Benefit From Zometa® (12/16/2005)
Researchers from Toronto, Canada, recently reported that the administration of Zometa (zoledronic acid) significantly improved pain control in women with progressive bone metastasis from breast cancer who had progression while receiving clodronate or pamidronate.
Risk Factors for Osteonecrosis of the Jaw from Bisphosphonates Defined (12/2/2005)
Researchers from Greece have reported that the use of bisphosphonates is associated with the development of osteonecrosis of the jaw with the most important risk factor being the time of exposure. The details of this report appeared in the December 1, 2005, issue of the Journal of Clinical Oncology.
Risk of Pelvic Fractures in Women Greater Following Radiation Therapy (12/1/2005)
Researchers from the University of Minnesota and the University of North Carolina have reported that women who have received radiation therapy to the pelvis for cancers of the cervix, rectum, or anus are at an increased risk for pelvic fractures compared to women with these types of cancer who did not undergo pelvic radiation.
Decompressive Surgery and Radiation Therapy Optimal for Metastatic Spinal Cord Compression. (7/25/2005)
Researchers concucting a multicenter trial at the University of Kentucky have determined that patients with non-hematologic metastatic tumors causing spinal cord compression have better outcomes with immediate surgery followed by radiation therapy than those who receive radiation alone.
Single Dose Radiotherapy Effective Palliation for Bone Metastasis (6/20/2005)
Researchers affiliated with the Radiation Therapy Oncology Group (RTOG) have reported that a short course of radiotherapy for palliation of painful bone metastases is as effective as a long course.
Cryoablation Effective for Reducing Pain Associated with Bone Metastasis (4/8/2005)
According to results presented at the 30th annual meeting of the Society of Interventional Radiation (SIR), cryoablation appears to provide effective pain relief for patients with bone metastasis.
Androgen Deprivation for Prostate Cancer Increases Bone Fractures (1/19/2005)
Researchers from the University of Texas at Galveston have reported that men receiving androgen deprivation and surviving at least 5 years after diagnosis had a fracture rate of 19.4% compared to 12.6% for comparable men not receiving such therapy.
Zometa® Reduces Skeletal Complications Compared to Placebo (11/9/2004)
In the first trial comparing Zometa® (zoledronic acid) to placebo (inactive substitute), Zometa® produced a significant clinical benefit in patients with bone metastases from breast cancer. These results were presented by Japanese researchers at the 29th Congress of the European Society of Medical Oncology (ESMO) held in Vienna Austria, October 29-November 2, 2004.
Long-Term Zometa™ Prevents Skeletal Complications in Men with Prostate Cancer (6/4/2004)
Researchers affiliated with the Zolendronic Acid Prostate Study Group have presented a 24 month follow-up of a clinical trial which randomly allocated men with bone metastases from prostate cancer to receive Zometa™ or placebo.
8 Gy in One Fraction Equivalent to 30 Gy in 10 Fractions for Palliation of Bone Metastasis (10/23/2003)
Researchers affiliated with the Radiation Treatment Oncology Group (RTOG) have reported preliminary data suggesting equivalency of palliation of painful bone metastasis with 8 Gy of radiation in a single fraction compared to the standard approach of 30 Gy in 10 fractions. If confirmed with longer follow-up this could represent significant cost savings as well as being more convenient for patients. The results of this randomized trial were presented at the 45th annual meeting of the American Society for Therapeutic Radiology and Oncology on October 20, 2003 in Salt Lake City.
Intravenous Zometa® Improves Bone Mineral Bone Density in Postmenopausal Women (2/28/2002)
Osteoporosis affects millions of postmenopausal women in the United States. Vertebral and hip fractures associated with osteoporosis are common features of aging in American women. The current preventative measures include: adequate calcium intake (at least 1200 mg daily for postmenopausal women) and adequate vitamin D intake (400 to 800 IU daily) and regular weight-bearing exercise, as well as avoidance of smoking and excessive alcohol consumption.
|
|
Patient Home
